Abstract:The COVID-19 pandemic disrupted access to cancer treatment. 1 COVID-19–related disruptions in treatment may have disproportionately affected individuals who experienced a high burden of COVID-19–related disease. 1 Our objective was to evaluate cancer treatment discontinuations (TDs) among patients with cancer who received a diagnosis of SARS-CoV-2 during their cancer treatment planning. Data for this cross-sectional study were obtained from the American Society of Clinical Oncology Survey on COVID-19 in Oncology Registry 2 (March 2020 to September 2022). Participating clinics included patients according to 2 eligibility criteria: (1) confirmed SARS-CoV-2 infection and (2) engagement in care at the time of infection. TD was defined as discontinued or canceled treatment with no plans of restart as reported by the clinic. Median (IQR) time between COVID-19 diagnosis date and the date TD status was ascertained was 2 (0-5) months. Owing to the descriptive nature of this analysis, we did not include an adjustment for multiple comparisons. 3 The study was reviewed by the Scientific Review Committee at Moffitt Cancer Center and was deemed as nonhuman participants research. The study was reported in accordance with the STROBE reporting guidelines. 4 Further details regarding the study methods have been previously published 2 and are shown in Supplement 1. The study population included 3812 patients (3125 patients [82%] aged ≥50 years; 2286 female [60%]; 2595 non-Hispanic White patients [68%]; 443 Hispanic patients [12%]; and 3290 patients living with ≤2 comorbidities [86%]) (Table). Overall, the prevalence of TD was 5.3% (200 of 3182 patients), with 3454 (90.6%) scheduled for drug-based therapy, 361 (9.5%) for radiation, 216 (5.7%) for surgery, and 30 (0.8%) transplant or cellular therapy. Controlling for other factors, non-Hispanic Asian patients had a much higher likelihood of experiencing cancer TD vs their non-Hispanic White counterparts (adjusted prevalence ratio [aPR], 1.62; 95% CI, 1.13-2.32) (Figure). Clinical factors associated with elevated likelihood of cancer TD included a higher (≥3) Eastern Cooperative Oncology Group score (adjusted prevalence ratio [aPR], 2.61; 95% CI, 1.12-4.36) and diagnosis with a gastrointestinal cancer (aPR, 2.13; 95% CI, 1.29-3.52). Severe COVID-19 outcomes were associated with a higher likelihood of cancer TD. Patients with stable cancer at COVID-19 diagnosis were less likely to experience cancer TD compared with those with progressing cancer (aPR, 0.51; 95% CI, 0.36-0.71). To our knowledge, this cross-sectional study of cancer treatment TD is novel because we focus on a population of patients with cancer who experienced severe interruptions in care during the COVID-19 pandemic. Importantly, TD was more likely to occur during the early phases of the pandemic, which may be due to multiple reasons such as availability of COVID-19 vaccination, and changes in response of health care systems once safety protocols were established. 1 We found that non-Hispanic Asian patients with cancer were most likely to experience TD. Multiple factors may have led to this racial inequity in receipt of cancer treatment, including difficulties leveraging telehealth due to language barriers among older Asian patients and the higher likelihood of hospitalization and death due to COVID-19 compared with White adults. 5 Clinical factors identified pertinent to cancer TD, such as gastrointestinal cancer diagnosis or severe COVID-19 disease, is similar to prior analysis that focused on any cancer treatment delays of at least 14 days. 6 Of note, cancer TD was less likely to occur among patients with stable cancer vs those with progressing cancers. This may suggest that patients already engaged in care were able to continue treatment. An important limitation of our data is that the type of cancer treatment (ie, adjuvant, palliative) was not available, which may have affected the risk or benefit for completing treatment. Nonetheless, our findings suggest long-term consequences of cancer treatment cancellations should be monitored to identify any potential exacerbations in inequities in cancer outcomes due to the COVID-19 pandemic. Accepted for Publication: March 17, 2024. Published: May 23, 2024. doi:10.1001/jamanetworkopen.2024.11859 Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2024 Islam JY et al. JAMA Network Open . Corresponding Author: Jessica Y. Islam, PhD, MPH, Center for Immunization and Infection in Cancer, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612 (jessica.islam@moffitt.org). Author Contributions: Dr Islam had full access to all of the data in the study and takes responsibility -Abstract Truncated-

Patients With Cancer and COVID-19 Who Discontinued Cancer Treatment